Skip to main content

Applications Of Monoclonal Antibodies

Applications Of Monoclonal Antibodies


What are MAbs made of?

An antibody is a protein that sticks to a specific protein called an antigen. Antibody plays a role circulating throughout the body until it finds the antigen target. 

Monoclonal antibodies are the antibodies that target an antigen, a cancer cell antigen, explicitly. These can be made in laboratories and are said to be monoclonal antibody drugs. 

These mAbs play a vital role in treating several diseases that include some types of cancers. Monoclonal antibody drugs can be prepared with researchers at work and proven effective against most treatments, including some cancers.

The mAbs are man-made proteins that are similar to human antibodies that form the immune system. There are four ways to make mAbs, and are named on the particular ones as follows: 

  • Murine

These proteins are made via mouse proteins and the names of the treatment associated with this mAb end in -omab.

  • Chimeric

These proteins combine part mouse and part human, with treatment names ending in -ximab.

  • Humanised

When attached to human proteins, these proteins are made out of small parts of the mouse proteins, and this treatment ends in -zumab.

  • Human

These proteins are made from human proteins, and treatment names end with -umab.

Possible side effects of Monoclonal Antibodies

Monoclonal antibodies are injected directly into the vein. The mAbs are themselves proteins and, when injected into the vein, can cause possible allergies or other reactions in the body. There are several potential side effects of monoclonal antibody drugs, as follows: 

    • Fever
    • Chills
    • Weakness
    • Headache
    • Nausea
    • Vomiting
    • Diarrhea
    • Low blood pressure
    • Rashes

These normal reactions are bearable and cured, yet when compared with chemotherapy drugs, the naked mAbs may have some severe side effects. Some monoclonal antibody drugs are specific to the antigen they target for, and they are as follows:

Bevacizumab aka Avastin

It targets the protein called VEGF, affecting the tumour blood vessel growth. This leads to high blood pressure, bleeding and clots, poor wound healing, and kidney damage.

Cetuximab aka Erbitux

This antibody mAb targets a protein called EGFR found on skin cells that may be benign or malignant. This drug can cause severe rashes for some patients.


At GeNext Genomics, we take pride in serving the industry with high-quality monoclonal antibody drugs products and services. With us, we have a team of skilled scientists and experienced professionals at work who cater to all your requirements. They are the reason behind GeNext Genomics to reach research goals and meet quality industry standards.

We believe in building the requirements with precision and top-most accuracy, even creating a humanized monoclonal antibody. We help the industry leaders to achieve their products by using our high-quality molecules. 


Labels:

Comments

Post a Comment

Popular posts from this blog

Impact of CDR Length on Antibody Functionality

  Image by freepik Antibodies rely on their complementarity-determining regions (CDRs) to recognize and bind antigens with high specificity. Among these regions, CDR3-particularly in the heavy chain (CDR-H3)-exhibits remarkable length diversity, directly influencing antigen recognition, structural stability, and therapeutic efficacy. Understanding how CDR length shapes antibody functionality is critical for advancing biologics, diagnostics, and immunotherapy . The Role of CDR-H3 in Antibody Diversity CDR-H3 is the most variable region in antibodies, formed by the recombination of V, D, and J gene segments. Its length ranges widely: Human antibodies: Typically, 11–20 amino acids (median 14), forming a near-normal distribution. Bovine antibodies: Feature ultra-long CDR-H3s (>50 residues) with unique "stalk-knob" structures for deep antigen binding. This length diversity expands the antibody repertoire, enabling recognition of structurally diverse antigens, from small molecul...
Post a Comment
Read more

TB: Time Is Running Out!

  Tuberculosis, caused by Mycobacterium tuberculosis , is a severe disease that mainly affects the lungs. TB remains the deadliest killer disease despite the current epidemic of COVID.  Like COVID, Tuberculosis bacteria can spread from person to person through sneezing and coughing And post COVID, and the Corona Virus has also posed a risk to people with TB. TB is a potentially fatal disease and has many causes, yet it is preventable and has a wide range of treatments in the market. When the TB affects the lungs, the disease results in being more contagious, with the person usually getting sick and close contact with them can make others affected too. Hence, it also brings isolation and social stigma to the patient suffering from TB.  It is mainly considered the disease of the poor as it is prevalent in a more crowded area with fewer resources. TB remains with us in a different form. TB Infection (Latent TB):  An individual with TB bacteria in the body who shows no s...
Post a Comment
Read more

Mastering Hybridoma Technology Steps: Uncover the Process at GenextGenomics

Dive into the nuanced process of Hybridoma Technology Steps on GenextGenomics. Our detailed guide elucidates the fusion, screening, and culturing stages crucial in producing monoclonal antibodies. Empower your research and development endeavors with insights into this groundbreaking biotech methodology. Explore GenextGenomics for a comprehensive understanding. Ready to leverage the potential of Hybridoma Technology? Join us to revolutionize your biotech journey today! Explore the Potential of Hybridoma Technology with GenextGenomics!
Post a Comment
Read more